Novartis Q4 2025 Earnings Call Highlights: Strong Full-Year Growth Amidst Q4 Challenges
ByAinvest
Wednesday, Feb 4, 2026 2:09 pm ET1min read
NVS--
Novartis AG reported an 8% increase in full-year sales and a 14% rise in core operating income. Key growth drivers like KISQALI, KESIMPTA, SCEMBLIX, and PLUVICTO showed significant sales increases. However, Q4 sales declined, and the company expects low single-digit sales growth and a decline in core operating income for 2026 due to generic competition and the Avidity deal causing a 1% to 2% core margin dilution.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet